Cannabis Investors: This Canadian Company Is Expected to Grow Sales by 1,100% in 2020

Should investors bet on a small-cap cannabis stock that has lost 75% in market value this year?

Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Shares of Auxly Cannabis Group (TSXV:XLY) have been pummeled over the last year. Similar to most pot stocks, Auxly has also burnt significant investor wealth. Auxly stock is trading at $0.64 and has lost 75% in market value since January 2018.

Has Auxly stock bottomed out? Will it gain momentum as we inch closer to 2019? If Auxly shares move higher, what will drive the stock rally?

Robust revenue growth

Auxly Cannabis is involved in the production of cannabis products for the medical, wellness, and adult-use markets. It also provides capital to fund cannabis facility expansions and operations in exchange for a portion of the cultivation production and a minority stake.

Auxly is bullish about long-term prospects in the marijuana space. According to Auxly management, the marijuana market in Canada is estimated to rise from $6 billion in 2019 to $11 billion in 2025. So, how will Auxly benefit from this growth?

Analysts tracking Auxly expect company sales to rise by 815% to $6.86 million in 2019. This growth is estimated to accelerate to 1,100% to $82.9 million in fiscal 2020. Analysts expect sales to reach $171 million in 2021.

Auxly Cannabis is valued at $408 million in terms of market cap. It is trading at a forward market-cap-to-sales multiple of 59.9. But this high multiple is supported by robust growth metrics.

Auxly’s revenue growth will also help the company expand profit margins. Analysts expect Auxly’s EBITDA to decline from -$28.1 million in 2018 to -$38.7 million in 2019. This is estimated to improve to -$13 million in 2020 and $49.3 million in 2021.

Operational and distribution strategy

Auxly has a diversified supply of raw cannabis with a cultivation capacity of 100,000 kg per annum. This includes production from wholly owned subsidiaries, offtake agreements, joint ventures, and streaming partners.

The company has created a portfolio of products and brands to gain traction in Canada’s growing marijuana market. Auxly is optimistic its brand portfolio will accelerate growth and appeal to a broad spectrum of current and potential customers. It’s brand platform includes internally developed products as well as those developed with a third-party licence.

Auxly aims to pursue a multi-faceted strategy to gain access to customers. This includes a wholly owned flagship retail store. Auxly is also looking to increase retail collaborations, invest on independent retailers and have supply agreements with provincial boards in Canada.

The average recreational cannabis buyer is not brand conscious. A cannabis customer is more loyal to the retail or online store, which is more accessible rather than a particular brand. The high regulatory nature of cannabis has resulted in a slow rollout of retail stores in Canada.

This has severely impacted revenue growth for most cannabis players. Auxly’s focus on the retail space will hold it in good stead as the industry continues to grapple with oversupply issues.

Auxly is also banking on the cannabis derivatives products market to drive sales. It has a facility at Dosecann, which is currently working on products such as cannabis-infused edibles, extracts, and wellness-based products.

In case the initial response to Cannabis 2.0 products in encouraging, investors can expect pot stocks, including Auxly, to gain momentum by the end of 2019.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Auxly Cannabis Group. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »